

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

Recombinant Anti-HLA-DPB1 antibody [EPR11226]

RRID:AB_2827533

Type: Antibody

Proper Citation

Abcam Cat# ab157210, RRID:AB_2827533

Antibody Information

URL: http://antibodyregistry.org/AB_2827533

Proper Citation: Abcam Cat# ab157210, RRID:AB_2827533

Target Antigen: HLA-DPB1

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IHC-P, ICC/IF, IP

Antibody Name: Recombinant Anti-HLA-DPB1 antibody [EPR11226]

Description: This recombinant targets HLA-DPB1

Target Organism: human

Clone ID: EPR11226

Antibody ID: AB_2827533

Vendor: Abcam

Catalog Number: ab157210

Record Creation Time: 20231110T032441+0000

Record Last Update: 20260901T042821+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-HLA-DPB1 antibody [EPR11226].

No alerts have been found for Recombinant Anti-HLA-DPB1 antibody [EPR11226].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chaudhary R, et al. (2025) Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research.

Weingarten-Gabbay S, et al. (2024) The HLA-II immunopeptidome of SARS-CoV-2. Cell reports, 43(1), 113596.

Jeong HO, et al. (2022) Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma. iScience, 25(11), 105358.

Johnson BE, et al. (2022) An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell reports. Medicine, 3(2), 100525.